← Leaderboards
Hideki Furuya
Methodist Hospital Research Institute
$1,806,978
Attributed
$2,410,693
Total exposure
4
Grants
3
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $816.2K · FY2021–25$1M$750K$500K$250K$0
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$2,410,693 · 4
By mechanism
R01$1,207,431 · 1
U54$780,109 · 2
R21$423,153 · 1
Top collaborators
- Charles J Rosser3 shared
Most similar at Methodist Hospital Research Institute
Same institution · by research overlap
- Dan Theodorescu$43,145,134
- Keith Syson Chan$11,391,028
- Rose Khavari$1,836,329
- Dipan J. Shah$2,960,139
- Tony Y. Hu$10,601,361
Others in their field
Other Emerging Leaders on “Bladder”
- Edward Burgard · Dignify Therapeutics, Llc$6,905,476
- Robert A Gaunt · University Of Chicago$6,521,096
- Richard Holubkov · Johns Hopkins University$5,981,450
- Vijay K Samineni · Washington University$5,421,526
- Kent W Mouw · Dana-Farber Cancer Inst$5,186,437
- Kristina L Penniston · University Of Wisconsin-Madison$5,027,500
Research focus
BladderTumor MicroenvironmentBiological MarkersMalignant Neoplasm Of Urinary BladderOverexpressionTissuesMalignant NeoplasmsHigh RiskIl8 GeneImmunoassayCohortClinicClinically RelevantClinical DiagnosisCarcinogensCandidate MarkerEducational WorkshopCombatAnimal ModelCancer PatientCarcinogenesisCancer ModelCessation Of LifeEarly Diagnosis
Grant awards (7)
A Multiplex Protein Biomarker-Based Immunoassay for the Early Detection of Bladder Cancer and its Implications in Tumor Biology$416,215
R01 · FY2025 · CA
Project 3$399,955
U54 · FY2025 · CA · contact PI
A Multiplex Protein Biomarker-Based Immunoassay for the Early Detection of Bladder Cancer and its Implications in Tumor Biology$414,870
R01 · FY2024 · CA
Project 3$380,154
U54 · FY2024 · CA · contact PI
A Multiplex Protein Biomarker-Based Immunoassay for the Early Detection of Bladder Cancer and its Implications in Tumor Biology$376,346
R01 · FY2023 · CA
Humanized anti-CXCL1 antibody for bladder cancer therapeutics$306,044
R21 · FY2022 · CA · contact PI
Humanized anti-CXCL1 antibody for bladder cancer therapeutics$117,109
R21 · FY2021 · CA · contact PI